Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues

[cafead]

via Pfizer’s Xeljanz (tofacitinib), used to treat conditions such as rheumatoid arthritis and ulcerative colitis, has encountered safety issues with the higher dose treatment arm of its post-marketing study of patients with cardiovascular risk factors.

article source